Evoke Pharma presented a study at the ACG 2024 Annual Meeting showing that their drug GIMOTI significantly reduced healthcare visits for diabetic gastroparesis patients using GLP-1 receptor agonists, with a 55% decrease in all-cause emergency department visits and 91% lower visits compared to oral metoclopramide.